EMA Authorised: Sotyktu (deucravacitinib) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

EMEA authorises Sotyktu (deucravacitinib) for its indication in psoriasis, marking a new approved therapy in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Sotyktu (Deucravacitinib)

Snippet

Status: Authorised. Therapeutic area: Psoriasis. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 10/04/2026